LBH589

Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Trial of LBH589 in Metastatic Thyroid Cancer

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Panobinostat (LBH589) in Patients With Metastatic Melanoma